ENSCW · Ensysce Biosciences, Inc.

Ensysce Biosciences reported Q1 FY2026 revenue of $961K, down 27.2% from $1.3M in the prior-year quarter. This decrease stems primarily from the timing of research activities eligible for funding under the MPAR grant, as noted in management's discussion. Despite lower revenue, the operating margin deteriorated sharply to -370.7%, driven by escalating expenses inherent to advancing product candidates into later stages of clinical development. These stages typically incur higher costs due to the increased size and duration of trials, explaining the 81.1% wider operating loss to -$3.6M from -$2.0M year-over-year.

Net income followed suit, expanding 82.8% deeper into loss territory at -$3.6M compared to -$1.9M last year. This reflects the company's ongoing investment in its single reportable segment focused on clinical-stage product candidates. On a per-share basis, diluted EPS showed improvement at -$0.52, a 62.6% less negative result than -$1.39, attributable to a larger share count that diluted the per-share impact of the loss.

Cash flow from operations consumed -$3.5M, up from -$1.7M prior year, underscoring negative cash flows that have persisted since inception alongside limited revenues and significant operating losses. Management anticipates continued losses for the foreseeable future, with general and administrative expenses expected to rise as headcount grows to support product development—contingent on securing financing.